A Stunning Failure of Covid Vaccination By Brian Simpson,

 Dr Peter McCullough reports that a peer-reviewed paper by Wu et al (abstract below, for the keen on technical details), has analysed 68 studies evaluating efficacy of Covid-19 vaccination. The 68 studies were biased to start with as only positive results got accepted by journal editors. But even here, it was found that effectiveness became virtually zero after a period of 168-195 days. This means that the vax was pointless from the beginning, or else there needs to be a continuous series of jabs. Since Covid is not a dangerous infection in most cases, with almost all vaccinated people now having it, and the vax has numerous side effects, the inference to make from the study is that the vax is indeed pointless.

https://petermcculloughmd.substack.com/p/meta-analysis-finds-massive-failure

By Peter A. McCullough, MD, MPH

Virtually every vaccinated person I meet has contracted COVID-19. Many still believe vaccination was worth the risk because they did not end up in the hospital in 2021 through the present day. Vaccine-takers tended to be younger working age individuals who were mandated by work or school, and therefore healthier than those not forced into taking the jab. In my practice, the senior citizens who took the vaccine tended to be healthier and far more worried about COVID-19. They were the first to get early treatment for the illness. Finally, we all saw COVID-19 illness become far milder on the second, third, and fourth infections because of natural immunity as we were faced with milder strains. So in the midst of this confounded set of relationships, how did the COVID-19 vaccines perform?

Wu et al, published a meta-analysis of 68 studies evaluating efficacy of COVID-19 vaccination. Keep in mind only favorable studies were accepted by editors. The results indicate a stunning failure of vaccination. Because the data are not from high-quality, prospective, double-blind, placebo-controlled, randomized trials, and publication bias, we must be conservative and consider the lower-bound of the confidence interval as the statistic of interest. This means that vaccine performance could be as bad as that number.

As you can see, most lower bounds are near or below zero at 168-195 days! That means just a few months after the shot, there is no detectable benefit even in the most biased studies. Hospitalization and death as an outcome must be considerably discounted since there was not control for early treatment, natural immunity, and progressively milder strains before Omicron. After Omicron, there is no benefit whatsoever for vaccination for the occurrence of SARS-CoV-2 or hospitalization/death."

https://pubmed.ncbi.nlm.nih.gov/36780914/#full-view-affiliation-1

Abstract

Background: Synthesising evidence on the long-term vaccine effectiveness of COVID-19 vaccines (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 [AZD1222; Oxford-AstraZeneca], and Ad26.COV2.S [Janssen]) against infections, hospitalisations, and mortality is crucial to making evidence-based pandemic policy decisions.

Methods: In this rapid living systematic evidence synthesis and meta-analysis, we searched EMBASE and the US National Institutes of Health's iSearch COVID-19 Portfolio, supplemented by manual searches of COVID-19-specific sources, until Dec 1, 2022, for studies that reported vaccine effectiveness immediately and at least 112 days after a primary vaccine series or at least 84 days after a booster dose. Single reviewers assessed titles, abstracts, and full-text articles, and extracted data, with a second reviewer verifying included studies. The primary outcomes were vaccine effectiveness against SARS-CoV-2 infections, hospitalisations, and mortality, which were assessed using three-level meta-analytic models. This study is registered with the National Collaborating Centre for Methods and Tools, review 473.

Findings: We screened 16 696 records at the title and abstract level, appraised 832 (50%) full texts, and initially included 73 (04%) studies. Of these, we excluded five (7%) studies because of critical risk of bias, leaving 68 (93%) studies that were extracted for analysis. For infections caused by any SARS-CoV-2 strain, vaccine effectiveness for the primary series reduced from 83% (95% CI 80-86) at baseline (14-42 days) to 62% (53-69) by 112-139 days. Vaccine effectiveness at baseline was 92% (88-94) for hospitalisations and 91% (85-95) for mortality, and reduced to 79% (65-87) at 224-251 days for hospitalisations and 86% (73-93) at 168-195 days for mortality. Estimated vaccine effectiveness was lower for the omicron variant for infections, hospitalisations, and mortality at baseline compared with that of other variants, but subsequent reductions occurred at a similar rate across variants. For booster doses, which covered mostly omicron studies, vaccine effectiveness at baseline was 70% (56-80) against infections and 89% (82-93) against hospitalisations, and reduced to 43% (14-62) against infections and 71% (51-83) against hospitalisations at 112 days or later. Not enough studies were available to report on booster vaccine effectiveness against mortality.

Interpretation: Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term."